Neuropsychiatric Effects of HIV Antiviral Medications

Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals

(2016) Julia L. Marcus et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data

(2016) Ella T. Nkhoma et al.   MEDICINE

Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz

(2016) Dhwanil A. Dalwadi et al.   PHARMACOLOGICAL RESEARCH

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

(2015) Laura Dickinson et al.   CLINICAL PHARMACOKINETICS

Improvement of Depression and Anxiety After Discontinuation of Long- Term Efavirenz Treatment

(2015) Khutso Mothapo et al.   CNS & Neurological Disorders-Drug Targets

Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study

(2015) E Pedrol et al.   HIV MEDICINE

Efavirenz and the CNS: what we already know and questions that need to be answered

(2015) Nadezda Apostolova et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study

(2015) Adriana Carvalhal et al.   JOURNAL OF NEUROVIROLOGY

Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients

(2015) Qing Ma et al.   JOURNAL OF NEUROVIROLOGY

Rilpivirine and Depression

(2015) David Freeman et al.   PSYCHOSOMATICS

Drug-induced Depression: a Case/Non Case Study in the French Pharmacovigilance Database

(2015) Claire Lafay-Chebassier et al.   THERAPIE

Overdose of dolutegravir in combination with tenofovir disaproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient

(2015) Marcel Lee et al.   AIDS Research and Therapy

The Cerebrospinal Fluid HIV Risk Score for Assessing Central Nervous System Activity in Persons With HIV

(2014) E. R. Hammond et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide

(2014) Katie R. Mollan et al.   ANNALS OF INTERNAL MEDICINE

Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility

(2014) Massimiliano Fabbiani et al.   ANTIVIRAL THERAPY

Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients

(2014) L. Curtis et al.   HIV CLINICAL TRIALS

Antiretroviral Treatment of Adult HIV Infection

(2014) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz

(2014) A. Blas-Garcia et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Involvement of Nitric Oxide in the Mitochondrial Action of Efavirenz: A Differential Effect on Neurons and Glial Cells

(2014) Nadezda Apostolova et al.   JOURNAL OF INFECTIOUS DISEASES

Neuronal Bioenergetics and Acute Mitochondrial Dysfunction: A Clue to Understanding the Central Nervous System Side Effects of Efavirenz

(2014) Haryes A. Funes et al.   JOURNAL OF INFECTIOUS DISEASES

Neuropsychiatric Complications of Efavirenz Therapy: Suggestions for a New Research Paradigm

(2014) Stefan Sütterlin et al.   JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES

The relationship of CPE to HIV dementia: Slain by an ugly fact?

(2014) J. R. Berger et al.   NEUROLOGY

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

(2014) E. C. Caniglia et al.   NEUROLOGY

Efavirenz Promotes β-Secretase Expression and Increased Aβ1-40,42 via Oxidative Stress and Reduced Microglial Phagocytosis: Implications for HIV Associated Neurocognitive Disorders (HAND)

(2014) Lecia A. M. Brown et al.   PLoS One

No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database

(2014) Andrew A Napoli et al.   Journal of the International AIDS Society

Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system

(2013) Markus Hecht et al.   AIDS

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

(2013) Matteo Vassallo et al.   AIDS

8-Hydroxy-efavirenz, the Primary Metabolite of the Antiretroviral Drug Efavirenz, Stimulates the Glycolytic Flux in Cultured Rat Astrocytes

(2013) Maria Brandmann et al.   NEUROCHEMICAL RESEARCH

The HIV Antiretroviral Drug Efavirenz has LSD-Like Properties

(2013) Michael B Gatch et al.   NEUROPSYCHOPHARMACOLOGY

Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score

(2012) Y Kahouadji et al.   HIV MEDICINE

Severe insomnia related to high concentrations of raltegravir

(2011) Céline Eiden et al.   AIDS

The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?

(2011) Magnus Gisslén et al.   BMC INFECTIOUS DISEASES

Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research

(2011) Lucette A Cysique et al.   BMC Neurology

Long-Term Safety from the Raltegravir Clinical Development Program

(2011) Hedy Teppler et al.   CURRENT HIV RESEARCH

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

(2011) Jean-Michel Molina et al.   LANCET

Survival after neuroAIDS: Association with antiretroviral CNS Penetration-Effectiveness score

(2011) E. Lanoy et al.   NEUROLOGY

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients

(2011) N. Ciccarelli et al.   NEUROLOGY

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

(2010) Marlene Smurzynski et al.   AIDS

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine

(2010) Laura Waters et al.   AIDS

Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms

(2010) Luiz F. Ferrari et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s)

(2010) David B. Clifford et al.   HIV CLINICAL TRIALS

Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies

(2010) Brian Dean   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

African Mitochondrial DNA Subhaplogroups and Peripheral Neuropathy during Antiretroviral Therapy

(2010) Jeffrey A. Canter et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

(2010) Robert K. Heaton et al.   JOURNAL OF NEUROVIROLOGY

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

(2010) Verena Gounden et al.   AIDS Research and Therapy

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

(2009) Anton L Pozniak et al.   AIDS

Exacerbation of depression associated with starting raltegravir: a report of four cases

(2008) Marianne Harris et al.   AIDS

Cytokine Genotype Suggests a Role for Inflammation in Nucleoside Analog-Associated Sensory Neuropathy (NRTI-SN) and Predicts an Individual's NRTI-SN Risk

(2008) Catherine L. Cherry et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy

(2008) Ronald J. Ellis et al.   ANNALS OF NEUROLOGY

Mechanisms of Zidovudine-Induced Mitochondrial Toxicity and Myopathy

(2008) Erin R. Scruggs et al.   PHARMACOLOGY